天順股份(002800.SZ):配股申請被否
格隆匯11月11日丨天順股份(002800.SZ)公佈,公司於近日收到中國證監會下發的《關於不予核准新疆天順供應鏈股份有限公司配股申請的決定》(證監許可[2019]2001號)文件。
中國證監會第十八屆發行審核委員會於2019年9月9日舉行2019年第125次工作會議,依法對公司的配股申請進行了審核。發審委會議以投票方式對公司的配股申請進行了表決,同意票數未達5票,申請未獲通過。根據《證券法》、《上市公司證券發行管理辦法》(證監會令第30號)和《中國證券監督管理委員會發行審核委員會辦法》(證監會令第134號)等有關規定,依法對公司的配股申請作出不予核准的決定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.